Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function

Journal of Diabetes Investigation

Volumn 4, Issue 6, 2013, Pages 585-594

  Usui, Ryota ^a   Yabe, Daisuke ^a   Kuwata, Hitoshi ^a   Fujiwara, Shuichi ^a   Watanabe, Koin ^a   Hyo, Takanori ^a   Yasuhara, Akihiro ^a   Iwasaki, Masahiro ^a   Kitatani, Naomi ^a   Kuwabara, Kyoko ^a   Yokota, Kayo ^a   Kurose, Takeshi ^a   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Cell function; Glucagon stimulation test; Glucagon like peptide 1 receptor agonist

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CELL FUNCTION; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; ENDOCRINE FUNCTION TEST; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN RELEASE; INTRAABDOMINAL FAT; JAPANESE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREDICTION; PRIORITY JOURNAL; RASH; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

EID: 84888438496     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12111     Document Type: Article

References (40)

1. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. Funakoshi S, Fujimoto S, Hamasaki A, et al. Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 2008; 82: 353-358.
5. Funakoshi S, Fujimoto S, Hamasaki A, et al. Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: comparison with C-peptide levels after glucagon load. J Diabetes Invest 2012; 2: 429-434.
6. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1999; 44: 1249-1258.
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
8. Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4, 900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care 2012; 35: 1165-1170.
9. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124: S3-S18.
10. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
11. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
12. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
13. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
14. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.
15. NovoNordiskPharmaLtd. Safety Information Letter: Ketoacidosis and hyperglycemia after switching from insulin therapy to human GLP-1 analogue Victoza 18 mg. In; 2010.
16. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605-610.
17. Hendriksen C, Faber OK, Drejer J, et al. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615-619.
18. Gjessing HJ, Matzen LE, Froland A, et al. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987; 10: 487-490.
19. Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patientes with type 2 diaebtes. J Diabetes Invest 2011; 2: 297-303.
20. Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011; 58: 315-322.
21. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
22. Kajinuma H, Kanazawa Y, Sando H, et al. Human plasma C-peptide immunoreactivity: its correlation with immunoreactive insulin in diabetes, and chronic liver and renal diseases. Endocrinol Jpn 1979; 26: 65-73.
23. Davidson JA, Brett J, Falahati A, et al. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 2011; 17: 345-355.
24. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
25. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
26. Bedogni G, Malavolti M, Severi S, et al. Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Clin Nutr 2002; 56: 1143-1148.
27. Malavolti M, Mussi C, Poli M, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol 2003; 30: 380-391.
28. Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on bodyweight: a meta-analysis. Exp Diabetes Res 2012; 2012: 672658.
29. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31: 2472-2488.
30. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
31. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153-156.
32. Goto A, Takaichi M, Kishimoto M, et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 2010; 57: 237-244.
33. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152-156.
34. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
35. Seino Y, Rasmussen MF, Clauson P, et al. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. J Diabetes Invest 2012; 3: 388-395.
36. Albareda M, Rigla M, Rodriguez-Espinosa J, et al. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract 2005; 68: 202-206.
37. Lindstrom T, Arnqvist HJ, Ludvigsson J, et al. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment. Acta Endocrinol (Copenh) 1992; 126: 477-483.
38. Gutniak MK, Juntti-Berggren L, Hellstrom PM, et al. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19: 857-863.
39. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human GLP-1 analogue liraglutide as add-on to sulfonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 341-347.
40. Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012; 55: 2096-2108.